Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers

Yanaranop, Marut; Jantarateptewan, Natcha; Tiyayon, Jitima; Nakrangsee, Saranyu

doi:10.1097/igc.0000000000001277

Cited by 6 publications

(3 citation statements)

References 20 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Resultsmentioning

confidence: 99%

“…Multiple studies, including meta‐analyses, have highlighted the role of HE4 as a potential complement to CA 125, especially in differentiating benign endometriotic and inflammatory lesions in younger women 25,81–103 . Additional tumor markers (as in the ROMA test) have failed to improve significantly the discrimination between benign and malignant masses compared with CA 125 alone 53,81,84,91,96–109 . The combination of a more extended tumor marker profile, including the addition of carcinoembryonic antigen (CEA) and/or carbohydrate antigen (CA 19‐9) to CA 125, is useful mainly for differentiating between metastatic tumors from the gastrointestinal tract or pancreas and primary ovarian malignancy 110–113 .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors

Timmerman

Bourne

Landolfo

et al. 2021

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

The European Society of Gynaecological Oncology (ESGO), the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the International Ovarian Tumour Analysis (IOTA) group and the European Society for Gynaecological Endoscopy (ESGE) jointly developed clinically relevant and evidence-based statements on the preoperative diagnosis of ovarian tumors, including imaging techniques, biomarkers and prediction models.ESGO/ISUOG/IOTA/ESGE nominated a multidisciplinary international group, including expert practising clinicians and researchers who have demonstrated leadership and expertise in the preoperative diagnosis of ovarian tumors and management of patients with ovarian cancer (19 experts across Europe). A patient representative was also included in the group. To ensure that the statements were evidence-based, the current literature was reviewed and critically appraised.Preliminary statements were drafted based on the review of the relevant literature. During a conference call, the whole group discussed each preliminary statement and a first round of voting was carried out. Statements were removed when consensus among group members was not obtained. The voters had the opportunity to provide comments/suggestions with their votes. The statements were then revised accordingly. Another round of voting was carried out according to the same rules to allow the whole group to evaluate the revised version of the statements. The group achieved consensus on 18 statements.This Consensus Statement presents these ESGO/ ISUOG/IOTA/ESGE statements on the preoperative diagnosis of ovarian tumors and the assessment of carcinomatosis, together with a summary of the evidence supporting each statement.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors

Timmerman

Bourne

Landolfo

et al. 2021

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

show abstract

“…Multiple studies, including meta-analyses, have highlighted the role of HE4 as a potential complement to CA 125, especially in differentiating benign endometriotic and inflammatory lesions in younger women (Al Musalhi et al, 2016;Cao et al, 2018;Huang et al, 2018;Jacob et al, 2011;Jia et al, 2017;Kim et al, 2019;Kotowicz et al, 2015;Li et al, 2012;Lin et al, 2013;Lycke et al, 2018;Melo et al, 2018;Richards et al, 2015;Romagnolo et al, 2016;Sandri et al, 2013;Shin et al, 2020;Stiekema et al, 2014;Terlikowska et al, 2016;Van Gorp et al, 2012;Wang et al, 2014;Xu et al, 2016;Yanaranop et al, 2017;Yanaranop et al, 2018;Yu et al, 2012;Zhang et al, 2015). Additional tumour markers (as in the ROMA test) have failed to improve significantly the discrimination between benign and malignant masses compared with CA 125 alone (Chen et al, 2015;Choi et al, 2020;Cui et al, 2019;Huy et al, 2018;Kaijser, Van Gorp, et al, 2014;Kim et al, 2019;Kotowicz et al, 2015;Lycke et al, 2018;Melo et al, 2018;Piovano et al, 2017;Romagnolo et al, 2016;Sandri et al, 2013;…”

Section: Tumour Markersmentioning

confidence: 99%

ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumours

Timmerman¹,

Bourne²,

Landolfo³

et al. 2021

Facts Views Vis ObGyn

View full text Add to dashboard Cite

The European Society of Gynaecological Oncology (ESGO), the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the International Ovarian Tumour Analysis (IOTA) group and the European Society for Gynaecological Endoscopy (ESGE) jointly developed clinically relevant and evidence-based statements on the preoperative diagnosis of ovarian tumours, including imaging techniques, biomarkers and prediction models. ESGO/ISUOG/IOTA/ESGE nominated a multidisciplinary international group, including expert practising clinicians and researchers who have demonstrated leadership and expertise in the preoperative diagnosis of ovarian tumours and management of patients with ovarian cancer (19 experts across Europe). A patient representative was also included in the group. To ensure that the statements were evidence-based, the current literature was reviewed and critically appraised. Preliminary statements were drafted based on the review of the relevant literature. During a conference call, the whole group discussed each preliminary statement and a first round of voting was carried out. Statements were removed when a consensus among group members was not obtained. The voters had the opportunity to provide comments/suggestions with their votes. The statements were then revised accordingly. Another round of voting was carried out according to the same rules to allow the whole group to evaluate the revised version of the statements. The group achieved consensus on 18 statements. This Consensus Statement presents these ESGO/ISUOG/IOTA/ESGE statements on the preoperative diagnosis of ovarian tumours and the assessment of carcinomatosis, together with a summary of the evidence supporting each statement.

show abstract

Deep Learning Radiomics Nomogram Based on Magnetic Resonance Imaging for Differentiating Type I/II Epithelial Ovarian Cancer

Wei,

Feng,

Wang

et al. 2024

Academic Radiology

View full text Add to dashboard Cite

Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers

Abstract: In women who present with pelvic masses, ROMA performed very well in distinguishing between noncancer lesions and EOCs but the combined HE4 and CA125 test was more effective in predicting EOC types.

Cited by 6 publications

References 20 publications

ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors

ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors

ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumours

Deep Learning Radiomics Nomogram Based on Magnetic Resonance Imaging for Differentiating Type I/II Epithelial Ovarian Cancer

Contact Info

Product

Resources

About